Investor directory

Future Planet Capital

Founded in London in 2016, Future Planet Capital is a venture capital firm investing in growth-stage companies from top global universities. It focuses on breakthrough technologies addressing challenges in climate change, health, education, and sustainable growth.
http://futureplanetcapital.com
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=413867682
https://www.privateequityinternational.com/database/#/profile?id=18843

Daniel Gaize

Investment Executive

Douglas Hansen-Luke

Executive Chairman

Sakura Holloway

Investment Director

David Knox

Founding Director and Shareholder

Alexander Leigh

Investment Director

Past deals in Birmingham

Midven

Acquisition in 2021
Midven, established in 1990 and headquartered in Birmingham, UK, is a venture capital firm specialising in early-stage and growth-stage investments. It focuses on providing up to £1 million to fast-growing small and medium-sized enterprises (SMEs), supporting their expansion and development. Midven's team, comprising experienced and hands-on investment managers, offers not only capital but also strategic guidance to its portfolio companies.

Linear Diagnostics

Venture Round in 2021
Linear Diagnostics develops a proprietary diagnostic platform technology that enables rapid, simultaneous detection of multiple targets using a single reagent. Its core innovation, linear dichroism, facilitates molecular diagnostics tests across various sectors, including infectious diseases and food safety.

Linear Diagnostics

Venture Round in 2019
Linear Diagnostics develops a proprietary diagnostic platform technology that enables rapid, simultaneous detection of multiple targets using a single reagent. Its core innovation, linear dichroism, facilitates molecular diagnostics tests across various sectors, including infectious diseases and food safety.

Linear Diagnostics

Seed Round in 2017
Linear Diagnostics develops a proprietary diagnostic platform technology that enables rapid, simultaneous detection of multiple targets using a single reagent. Its core innovation, linear dichroism, facilitates molecular diagnostics tests across various sectors, including infectious diseases and food safety.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.